Liver and Fat Regulation in Overweight Adolescent Girls

NCT02157974 on ClinicalTrials.gov · last registry update 2024-06-04

Finished December 2022, after enrolling 92 people. Primary outcome, as filed: Hepatic Glucose Release. exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2/P3
Drug: exenatide
Bydureon, Byetta
Sponsor: University of Colorado, Denver
Sponsor type: Other
Enrollment: 92
Started: 2014-08
Primary completion: 2022-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Hepatic Glucose Release

Conditions studied

Hepatic Steatosis · Polycystic Ovarian Syndrome · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.